Alerts will be sent to your verified email
Verify EmailABBOTINDIA
Abbott India
|
Alkem Laboratories
|
Aurobindo Pharma
|
|
---|---|---|---|
Operational Metrics
|
|||
Pharmaceutical Sector
|
|||
Domestic Sales Growth - YoY
|
7.2 % | 7.1 % | n/a |
R&D as a % of Total Sales
|
0.02 % | 4.3 % | 5.3 % |
Financials
|
|||
5 yr Average ROE
|
28.3 % | 17.42 % | 13.97 % |
5yr average Equity Multiplier
|
1.45 | 1.42 | 1.51 |
5yr Average Asset Turnover Ratio
|
1.15 | 0.89 | 0.71 |
5yr Avg Net Profit Margin
|
17.01 % | 13.9 % | 12.77 % |
Price to Book
|
17.18 | 5.63 | 2.37 |
P/E
|
47.08 | 30.48 | 20.47 |
5yr Avg Cash Conversion Cycle
|
-49.8 Days | -31.98 Days | -49.62 Days |
Inventory Days
|
47.03 Days | 55.32 Days | 59.48 Days |
Days Receivable
|
19.26 Days | 41.28 Days | 28.34 Days |
Days Payable
|
108.53 Days | 114.28 Days | 115.71 Days |
5yr Average Interest Coverage Ratio
|
83.18 | 24.2 | 43.78 |
5yr Avg ROCE
|
36.46 % | 22.93 % | 16.69 % |
5yr Avg Operating Profit Margin
|
21.84 % | 18.1 % | 19.28 % |
5 yr average Debt to Equity
|
0.0 | 0.21 | 0.21 |
5yr CAGR Net Profit
|
15.17 % | 9.76 % | 2.21 % |
5yr Average Return on Assets
|
19.59 % | 12.26 % | 9.18 % |
Shareholdings
|
|||
Promoter Holding
|
74.99 % | 55.66 % | 51.82 % |
Share Pledged by Promoters
|
0.0 | 0.0 | 20.39 % |
Change in Promoter Holding (3 Yrs)
|
0.0 | -3.18 % | -0.01 % |
Change in Mutual Fund Holding (3 Yrs)
|
4.05 % | 6.99 % | 9.25 % |
Abbott India
|
Alkem Laboratories
|
Aurobindo Pharma
|
|
---|---|---|---|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Acute vs Chronic
|
Acute vs Chronic
|
-
|
-
|
Dosage Form Break-Up
|
Dosage Form Break-Up
|
-
|
-
|
Brand Wise Break-Up
|
Brand Wise Break-Up
|
-
|
-
|